A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia.

Alexandre BazinetFaezeh DarbaniyanTapan Mahendra Kadia Sangeetha Venugopal Rashmi Kanagal-Shamana Courtney D D DiNardoGautam BorthakurElias J Jabbour Naval G Daver Naveen PemmarajuMarina Y KonoplevaFarhad RavandiKoiji SasakiKelly S ChienDanielle HammondSherry A PierceHagop M KantarjianGuillermo Garcia Manero Guillermo Montalban Bravo

Published in: Cancer (2022)

CLAD/LDAC/HMA-based regimens are effective in a subset of patients with higher risk CMML and sAML arising from CMML who have not previously experienced HMA failure. These findings must be confirmed in prospective studies.

Keyphrases

acute myeloid leukemia
low dose
allogeneic hematopoietic stem cell transplantation
high dose
bone marrow
case control